Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
Hansa is deploying Cradle’s end-to-end platform to develop novel immunomodulatory therapies in autoimmune disease.
LUND, Sweden and AMSTERDAM, The Netherlands, October 1, 2026 – Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a partnership with Cradle, which builds the leading AI-driven protein design and engineering platform for biologics. Hansa will use Cradle’s end-to-end platform across its discovery pipeline to design, optimize, and advance novel therapeutic candidates. Leveraging Cradle’s AI driven protein engineering platform, the companies aim to accelerate the development of new therapeutics for patients with severe autoimmune diseases.
